Supaglutide
A Study of Supaglutide in Chinese Type 2 Diabetes Patients
Shanghai Yinnuo Pharmaceutical Technology Co. · Phase 2 · Completed · Enrollment 40
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Supaglutide (Part A) | n/r | n/r | n/r | n/r |
| Placebo(Part A) | n/r | n/r | n/r | n/r |
| Supaglutide (Part B) | n/r | n/r | n/r | n/r |
| Placebo (Part B) | n/r | n/r | n/r | n/r |
Not shown
- Supaglutide (Part A): endpoint not reported
- Placebo(Part A): endpoint not reported
- Supaglutide (Part B): endpoint not reported
- Placebo (Part B): endpoint not reported